Survival Benefit Regardless of Prior Treatment
in Patients With Adenocarcinoma
Overall Survival by
Prior First-line Chemotherapy
Nintedanib
Placebo
No. at risk
Probability of survival (%)
Prior taxane treatment
100
80
60
40
20
0
Time (months)
0
4 8 12 16 20 24
36
28 32
77 66 55 44 34 28 23
4
16
65 53 40 30 21 16 11
1
8
8
2
Prior pemetrexed treatment
100
80
60
40
20
0
Time (months)
0
4 8 12 16 20 24
36
28 32
61 48 37 30 24 17 14
0
7
62 65 49 31 25 18 13
1
12
2
5
Prior bevacizumab treatment
100
80
60
40
20
0
Time (months)
0
4 8 12 16 20 24
36
28 32
24 20 15 14 11 8 7
2
6
21 15 12
7
6 4 4
0
2
4
1
Nintedanib +
docetaxel
Placebo +
docetaxel
Median OS
(months)
15.1
11.6
HR = 0.75 (95% CI: 0.51–1.11)
Nintedanib +
docetaxel
Placebo +
docetaxel
Median OS
(months)
12.0
8.0
HR = 0.79 (95% CI: 0.53–1.18)
Nintedanib +
docetaxel
Placebo +
docetaxel
Median OS
(months)
14.9
8.7
HR = 0.61 (95% CI: 0.31–1.20)
